Kunwei Shen

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, Joseph Gligorov, Fabrice André et al. · Annals of Oncology · 2021 · 689 citations · Full text

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Fabrice André, Ruth O’Regan, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2014 · 489 citations

Advanced Breast Cancer, Breast Oncology, Oncology +8

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Binghe Xu, Min Yan, Fei Ma et al. · The Lancet Oncology · 2021 · 372 citations

Capecitabine Versus Lapatinib, Breast Oncology, Medicine +8

Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24

Tao Yu, Shucheng Gan, Qingchen Zhu et al. · Nature Communications · 2019 · 332 citations · Full text

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Sara A. Hurvitz, Fabrice André, Zefei Jiang et al. · The Lancet Oncology · 2015 · 300 citations

Breast Oncology, Oncology, Pharmacology +7